公开(公告)号：US11180571B2

公开(公告)日：2021-11-23

申请号：US16587606

申请日：2019-09-30

申请人： Hoffmann-La Roche Inc.

发明人： Thomas Hofer ,  Maximiliane Koenig ,  Ekkehard Moessner ,  Jens Niewoehner ,  Tina Weinzierl ,  Laurent Lariviere

IPC分类号： C07K16/30 ,  A61P35/00 ,  C07K16/28

摘要： The present invention generally relates to antibodies that bind to STEAP-1, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

公开(公告)号：US20210230278A1

公开(公告)日：2021-07-29

申请号：US17125500

申请日：2020-12-17

申请人： Hoffmann-La Roche Inc.

发明人： Tina Weinzierl ,  Lydia Jasmin Hanisch ,  Alexander Bujotzek ,  Alejandro Carpy Gutierrez Cirlos ,  Stefan Klostermann ,  Christian Klein ,  Simon Patrick Keiser ,  Tanja Fauti ,  Estelle Marrer-Berger ,  Pablo Umaña

IPC分类号： C07K16/28 ,  C07K16/30 ,  A61P35/00

摘要： The present invention generally relates to antibodies that bind to HLA-A2/MAGE-A4, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

公开(公告)号：US20190031784A1

公开(公告)日：2019-01-31

申请号：US16016209

申请日：2018-06-22

申请人： Hoffmann-La Roche Inc.

发明人： Marina Bacac ,  Peter Bruenker ,  Anne Freimoser-Grundschober ,  Ralf Hosse ,  Christian Klein ,  Ekkehard Moessner ,  Pablo Umana ,  Tina Weinzierl

IPC分类号： C07K16/46 ,  C07K16/28 ,  A61K39/00

摘要： The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.